tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of James Molloy, 58 are a BUY (95.08%), 3 are a HOLD (4.92%).
Analyst James Molloy, currently employed at ALLIANCE GLOBAL PARTNERS, carries an average stock price target met ratio of 40.44% that have a potential upside of 51.39% achieved within 319 days. Previously, James Molloy worked at LAIDLAW, JANNEY, SUMMER STREET.
James Molloy’s has documented 107 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on SLS, Sellas Life Sciences Group at 08-Jul-2026.
Analyst best performing recommendations are on ORMP (ORAMED PHARMACEUTICALS).
The best stock recommendation documented was for AVDL (AVADEL PHARMACEUTICALS PLC) at 11/13/2013. The price target of $11 was fulfilled within 62 days with a profit of $4.63 (72.68%) receiving and performance score of 11.72.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 03-Aug-2023
$19
$20
3 years 8 days ago
(27-Sep-2023)
2/8 (25%)
$0.42 (2.26%)
86
Buy Since 12-Jan-2022
$19
$15
3 years 8 days ago
(27-Sep-2023)
3/16 (18.75%)
$0.42 (2.26%)
57
Buy Since 03-Aug-2023
$19
$19
3 years 8 days ago
(27-Sep-2023)
11/14 (78.57%)
$0.42 (2.26%)
66
Hold Since 10-Nov-2020
$19
$13
3 years 8 days ago
(27-Sep-2023)
12/25 (48%)
$0.42 (2.26%)
39
Buy Since 10-Nov-2020
$19
$18
3 years 9 days ago
(26-Sep-2023)
6/27 (22.22%)
$0.29 (1.55%)
66
Which stock is James Molloy most bullish on?
What Year was the first public recommendation made by James Molloy?
